ES2060310T3 - Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion. - Google Patents

Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion.

Info

Publication number
ES2060310T3
ES2060310T3 ES91400163T ES91400163T ES2060310T3 ES 2060310 T3 ES2060310 T3 ES 2060310T3 ES 91400163 T ES91400163 T ES 91400163T ES 91400163 T ES91400163 T ES 91400163T ES 2060310 T3 ES2060310 T3 ES 2060310T3
Authority
ES
Spain
Prior art keywords
phenylalanine
diseases
treatment
miristoilation
miristoil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91400163T
Other languages
English (en)
Spanish (es)
Inventor
Michel Vincent
Georges Remond
Yolande Herve
Jean-Albert Boutin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Application granted granted Critical
Publication of ES2060310T3 publication Critical patent/ES2060310T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES91400163T 1990-01-25 1991-01-25 Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion. Expired - Lifetime ES2060310T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9000834A FR2657259A1 (fr) 1990-01-25 1990-01-25 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.

Publications (1)

Publication Number Publication Date
ES2060310T3 true ES2060310T3 (es) 1994-11-16

Family

ID=9393082

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91400163T Expired - Lifetime ES2060310T3 (es) 1990-01-25 1991-01-25 Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion.

Country Status (14)

Country Link
US (1) US5164414A (show.php)
EP (1) EP0443891B1 (show.php)
JP (1) JPH0717503B2 (show.php)
AT (1) ATE94387T1 (show.php)
AU (1) AU633395B2 (show.php)
CA (1) CA2034861A1 (show.php)
DE (1) DE69100364T2 (show.php)
DK (1) DK0443891T3 (show.php)
ES (1) ES2060310T3 (show.php)
FR (1) FR2657259A1 (show.php)
IE (1) IE65573B1 (show.php)
OA (1) OA09478A (show.php)
PT (1) PT96571A (show.php)
ZA (1) ZA91574B (show.php)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672598A1 (fr) * 1991-02-11 1992-08-14 Adir Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5599947A (en) * 1993-01-14 1997-02-04 G. D. Searle & Co. Fatty acid analogs and prodrugs
US6407125B1 (en) 1995-12-29 2002-06-18 Novactyl, Inc. Pharmacological agent and method of treatment
US6127393A (en) * 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US6579891B1 (en) 1995-12-29 2003-06-17 Novactyl, Inc. Agent and method for prevention and treatment of cancer in animals
US6743771B2 (en) 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US6441009B1 (en) 1998-08-01 2002-08-27 Novactyl, Inc. Agent and method of preventing and treating heavy metal exposure and toxicity
CA2388754C (en) * 1999-10-13 2010-07-13 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
US6403618B1 (en) 2000-02-15 2002-06-11 Novactyl, Inc. Agent and method for controlling angiogenesis
AU2002318427A1 (en) * 2001-06-25 2003-03-03 University Of Massachusetts N-fatty acid-amino acid conjugates and therapeutic uses
DE10353806A1 (de) * 2003-11-14 2005-07-07 Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Gesundheit, dieses vertreten durch das Robert-Koch-Institut, vertreten durch seinen Präsidenten Verwendung von Aminosäure- und Zucker-Amphiphilen zur Inaktivierung von lipidumhüllten Viren
US7544714B2 (en) * 2004-07-16 2009-06-09 University Of Massachusetts Lipid-amino acid conjugates and methods of use
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
ES2937269T3 (es) 2011-07-22 2023-03-27 Pacylex Pharmaceuticals Inc Letalidad sintética y el tratamiento del cáncer
EP2830437B1 (en) 2012-03-30 2018-12-26 Givaudan SA N-acylated 1-aminocycloalkyl carboxylic acids as food flavouring compounds
JP6224072B2 (ja) 2012-03-30 2017-11-01 ジボダン エス エー フレーバープロフィール食用組成物の改良のためのｎ−アシル−アミノ酸誘導体
US10711230B2 (en) 2012-03-30 2020-07-14 Givaudan Sa N-acyl proline derivatives as food flavoring compounds
BR112014023905B1 (pt) 2012-03-30 2021-07-13 Givaudan Sa Composições de sabor e comestíveis compreendendo derivados de metionina n-acilados e bebida calórica e não-calórica
WO2013148991A1 (en) 2012-03-30 2013-10-03 Givaudan S.A. N-acyl derivatives of gamma amino - butyric acid and and beta alanine as food flavouring compounds
US10836712B2 (en) 2012-03-30 2020-11-17 Givaudan S.A. Organic compounds
US10582715B2 (en) 2012-03-30 2020-03-10 Givaudan Sa Powder flavour composition
CA2890113C (en) * 2012-10-30 2023-01-17 Pacylex Pharmaceuticals Inc. Synthetic lethality and the treatment of cancer
WO2015050535A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
EP3052472B1 (en) 2013-10-02 2019-02-27 Givaudan S.A. N-acylated 2-aminoisobutyric acid compounds and flavour compositions containing them
US10674755B2 (en) 2013-10-02 2020-06-09 Givaudan S.A. Organic Compounds
WO2015048990A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
US10834950B2 (en) 2013-10-02 2020-11-17 Givaudan S.A. Organic compounds
WO2015048991A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
US10537127B2 (en) 2013-10-02 2020-01-21 Givaudan S.A. Organic compounds
GB201317424D0 (en) 2013-10-02 2013-11-13 Givaudan Sa Improvements in or relating to organic compounds
EP3325662B1 (en) 2015-07-17 2023-08-30 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778878A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides I
US4778877A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides II

Also Published As

Publication number Publication date
DE69100364T2 (de) 1994-04-21
ATE94387T1 (de) 1993-10-15
US5164414A (en) 1992-11-17
EP0443891B1 (fr) 1993-09-15
OA09478A (fr) 1992-11-15
PT96571A (pt) 1991-10-15
AU6998791A (en) 1991-08-01
IE65573B1 (en) 1995-11-01
AU633395B2 (en) 1993-01-28
DK0443891T3 (da) 1993-12-27
FR2657259B1 (show.php) 1994-08-19
ZA91574B (en) 1991-11-27
FR2657259A1 (fr) 1991-07-26
DE69100364D1 (de) 1993-10-21
JPH0717503B2 (ja) 1995-03-01
IE910242A1 (en) 1991-07-31
CA2034861A1 (fr) 1991-07-26
EP0443891A1 (fr) 1991-08-28
JPH04210916A (ja) 1992-08-03

Similar Documents

Publication Publication Date Title
ES2060310T3 (es) Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion.
NL300224I1 (nl) 3-Benzazepinzonen gesubstitueerd met een benzocyclobutyl-of indanylalkyla-minoalkylgroep, bruikbaar voor de behandeling van cardiovasculaire aandoeningen.
PT695758E (pt) Amidas e esteres de pentapeptidos inibidores de cancro humano
ES2069843T3 (es) Utilizacion de baclofen para la obtencion de medicamentos destinados al tratamiento de la angina de pecho.
FI875326A7 (fi) Valonsäteilyttäjälaite korvan lääketieteelliseen hoitoon.
KR890701107A (ko) 알쯔하이머 병 치료용 화합물들
ES2153665T3 (es) Usos terapeuticos de productos proteicos bactericidas/incrementadores de la permeabilidad (bpi) para la meningococemia humana.
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
ES2132556T3 (es) Nuevo derivado de benzo-tiadiazina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
ES2128348T3 (es) Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
FR2651435B1 (show.php)
ES2041845T3 (es) Empleo de 2-oxo-pirrolidon-1-acetamida para la determinacion de las velocidades glomerulares de filtracion en seres humanos.
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
ES499363A0 (es) Procedimiento para la obtencion de derivados de fenilpipera-cina de 1,3,4-oxadiazolilfenoles
ES2150418T3 (es) Composiciones farmaceuticas que comprenden calcitonina.
FI911533A7 (fi) Bentsoksatsiini-johdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö sairauksien hoitamiseen tai ennalta ehkäisemiseksi
MX9201258A (es) Compuestos para el tratamiento del cancer y procedimiento para su preparacion.
ES1034986Y (es) Aparato para el tratamiento del cuerpo humano.
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
SE8900564D0 (sv) Novel medicinal use
ES2141923T3 (es) Uso hipocolesterolemico, antiaterosclerotico e hipotrigliceridemico de derivados aminoacetilmercapto.
ES1022564Y (es) Armonizador electromagnetico de las alteraciones fisiologicas del cuerpo humano.
YU40098A (sh) Upotreba olanzapina za dobijanje leka

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 443891

Country of ref document: ES